ÎÛÎÛ²ÝÝ®ÊÓƵ

Maida Sewitch

Academic title(s): 

Associate Professor, ÎÛÎÛ²ÝÝ®ÊÓƵ University

Ìý

Maida Sewitch
Contact Information
Address: 

5252 boul de Maisonneuve O, Office 2B.44

Montreal, QC H4A 3S5

Phone: 
514-934-1934 Ext 44736
Degree(s): 

PhD

Areas of expertise: 

Colorectal cancer screening, epidemiology, inflammatory bowel disease

Biography: 

Dr. Sewitch received her MSc and PhD from the Department of Epidemiology and Biostatistics at ÎÛÎÛ²ÝÝ®ÊÓƵ University. After completing post-doctoral fellowships at the University of Montreal and ÎÛÎÛ²ÝÝ®ÊÓƵ University, she joined the Division of Gastroenterology at the ÎÛÎÛ²ÝÝ®ÊÓƵ University Health Centre and the Division of Clinical Epidemiology at the Research Institute of the ÎÛÎÛ²ÝÝ®ÊÓƵ University Health Centre. She has published over 100 peer-reviewed articles and presented her research at over 170 scientific conferences. She has received 32 operating grants as Principal Investigator or Co-Investigator, as well as career awards from the Canadian Cancer Society (2005-2011) and the Fonds de la Recherche en Santé du Québec (2005-2009; 2011-2013). Dr. Sewitch has been a Visiting Scholar at Emory University in Atlanta, Georgia (2015-2016) and at the Tianjin Nankai Hospital in Tianjin, China (2016). Dr Sewitch was the recipient of the 2017 Outstanding Faculty Mentor Award from the Epidemiology, Biostatistics and Occupational Health Student Society.

Dr. Sewitch is Lead of the Quality Innovation Committee of the Canadian Association of Gastroenterology. She is a member of the Women's Mentorship Program of the Canadian Association of Gastroenterology, and sits on the Executive Committee at the Centre for Outcomes Research and Evaluation. Dr. Sewitch is a peer-review committee member for both the Canadian Institutes of Health Research and the Cancer Research Society.

Selected publications: 
  1. Sewitch MJ, Jiang M, Grad R, Yaffe M, Pavilanis A, Joseph L, Barkun AN, Roper M. (2013). Feasibility of a call-in center to deliver colorectal cancer screening in primary care. Canadian Family Physician, 59:e550-e557.
  2. Fallone CA, Barkun AN, Silagyi A, Herba KM, Sewitch M, Martel M, Fallone SS. (2013). Prolonged duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy. Canadian Journal of Gastroenterology, 27(7); 397-402. Sewitch MJ, Jiang M, Fon Sing M, Barkun A, Joseph L. (2014). Screening polypectomy rates below quality benchmarks: a prospective study. World Journal of Gastroenterology, 20(43): 15943-16388.
  3. *Mosli M, Feagan B, Zou G, Sandborn W, D'Haens G, Khanna R, Behling C, Kaplan K, Driman D, Shakelton L, Baker K, Macdonald J, Vandervoort M, Samaan MA, Geboes K, Valasek M, Pai R, Langner C, Riddell RH, Harpaz N, Sewitch M, Peterson M, Stitt L, Levesque, B. (2015). Reproducibility of histological assessments of disease activity in UC. Gut, 64(11):1765-73.
  4. *Almadi M, Sewitch M, Barkun A, Martel M, Joseph L. (2015). Adenoma detection rates decline with increasing procedural hours in an endoscopist’s workload. Canadian Journal of Gastroenterology & Hepatology, 29(6):304-8.
  5. Bitton A Vutcovici M, Sewitch M, Suissa S, Brassard P. (2016). Mortality trends in Crohn's disease and ulcerative colitis: a population-based study in Québec, Canada. Inflammatory Bowel Diseases, 22(2):416-23.
  6. *Sharara N, Nolan S, Sewitch M, Martel M, Dias M, Barkun AN. (2016). Assessment of a colonoscopy triage sheet for use in a province-wide population-based colorectal screening program. Canadian Journal of Gastroenterology & Hepatology. 2016:4712192
  7. *Carpentier S, Sharara N, Barkun A, El Ouali S, Martel M, Sewitch MJ. (2016). Pilot validation study: Canadian global rating scale for colonoscopy services. Canadian Journal of Gastroenterology & Hepatology. doi: 10.1155/2016/6982739.
  8. Pembroke T, Deschenes M, Labouche B, Benmassaod AM, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein M, Sebastiani G. (2017). Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. Journal of Hepatology, 67(4):801-808.
  9. Battat R, Waqqas A, Bessissow T, Sewitch M, Rahme E, Nedjar H, Dionne S, Byer J, Zelikovic E, Waters P, Seidman E, Bitton A. (2017). Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study. European Journal of Gastroenterology & Hepatology, 29(12):1361-1367.
  10. Sewitch MJ, Azalgara VM, Fon Sing M. (2018). Screening indication associated with lower likelihood of minor adverse events in patients undergoing outpatient colonoscopy. Gastroenterology Nursing; 41(2): 159-164.
  11. Bitton A, Vutcovici M, Lytvyak E, Kachan N, Bressler B, Jones JL, Lakatos PL, Sewitch M, El-Matary W, Melmed GY, Nguyen GC, and the QI consensus group on behalf of the Promoting Access and Care through Centres of Excellence-PACE program. (2019). Selection of quality indicators in IBD: integrating physician and patient perspectives. Inflammatory Bowel Diseases, 10;25(2):403-409.
  12. Sewitch MJ, Fallone C, Ghali P, Lee G-E. (2019). What patients want in a smartphone app that supports colonoscopy preparation: a qualitative study to inform a user-centred smartphone app. Journal of Medical Internet Research Mhealth Uhealth, July 2 7(7):e12242.
Location: 
RI-MUHC
Back to top